Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome

Behavioural Brain Research

Volumn 291, Issue , 2015, Pages 164-171

  Qin, Mei ^a   Zeidler, Zachary ^a   Moulton, Kristen ^a   Krych, Leland ^a   Xia, Zengyan ^a   Smith, Carolyn B ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

FAAH; Fmr1 KO mice; Fragile X syndrome; Memory; Passive avoidance; Propofol

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANANDAMIDE; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; AMIDASE; AMIDE; ARACHIDONIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; CANNABINOID RECEPTOR ANTAGONIST; CARBAMIC ACID DERIVATIVE; CNR1 PROTEIN, MOUSE; CYCLOHEXYL CARBAMIC ACID 3'-CARBAMOYLBIPHENYL-3-YL ESTER; ENZYME INHIBITOR; FATTY-ACID AMIDE HYDROLASE; FMR1 PROTEIN, MOUSE; FRAGILE X MENTAL RETARDATION PROTEIN; PIPERIDINE DERIVATIVE; PROPOFOL; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; AVERSIVE BEHAVIOR; BRAIN FUNCTION; CATALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME METABOLISM; FRAGILE X SYNDROME; FUNCTIONAL ASSESSMENT; LATENT PERIOD; MALE; MEMORY; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PASSIVE AVOIDANCE TEST; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; SOCIAL INTERACTION; STIMULUS RESPONSE; TASK PERFORMANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; AVOIDANCE BEHAVIOR; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; SOCIAL BEHAVIOR;

AMIDOHYDROLASES; ANIMALS; ANXIETY; ARACHIDONIC ACIDS; AVOIDANCE LEARNING; BENZAMIDES; CANNABINOID RECEPTOR ANTAGONISTS; CARBAMATES; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; ENZYME INHIBITORS; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; MALE; MEMORY; MICE, INBRED C57BL; MICE, KNOCKOUT; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PROPOFOL; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, GABA-A; SOCIAL BEHAVIOR;

EID: 84930659595     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.05.003     Document Type: Article

References (26)

1. Darnell J.C., Van Driesche S.J., Zhang C., Hung K.Y., Mele A., Fraser C.E., et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011, 146:247-261.
2. Qin M., Kang J., Burlin T.V., Jiang C., Smith C.B. Post-adolescent changes in regional cerebral protein synthesis: an in vivo study in the Fmr1 null mouse. J Neurosci 2005, 25:5087-5095.
3. Qin M., Schmidt K.C., Zametkin A.J., Bishu S., Horowitz L.M., Burlin T.V., et al. Altered cerebral protein synthesis in fragile X syndrome: studies in human subjects and knockout mice. J Cereb Blood Flow Metab 2013, 33:499-507.
4. 11C]leucine and PET in healthy male subjects. J Cereb Blood Flow Metab 2009, 29:1035-1047.
5. Qin M., Kang J., Smith C.B. Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A 2002, 99:15758-15763.
6. Liu Z.H., Chuang D.M., Smith C.B. Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. Int J Neuropsychopharmacol 2011, 14:618-630.
7. Ding Q., Sethna F., Wang H. Behavioral analysis of male and female Fmr1 knockout mice on C57BL/6 background. Behav Brain Res 2014, 271:72-78.
8. Hauer D., Ratano P., Morena M., Scaccianoce S., Briegel I., Palmery M., et al. Propofol enhances memory formation via an interaction with the endocannabinoid system. Anesthesiology 2011, 114:1380-1388.
9. Trapani G., Altomare C., Liso G., Sanna E., Biggio G. Propofol in anesthesia. Mechanism of action, structure-activity relationships, and drug delivery. Curr Med Chem 2000, 7:249-271.
10. Patel S., Wohlfeil E.R., Rademacher D.J., Carrier E.J., Perry L.J., Kundu A., et al. The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol 2003, 139:1005-1013.
11. Maccarrone M., Rossi S., Bari M., De Chiara V., Rapino C., Musella A., et al. Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking FMRP and BC1 RNA. Neuropsychopharmacology 2010, 35:1500-1509.
12. Zhang L., Alger B.E. Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome. J Neurosci 2010, 30:5724-5729.
13. Jung K.M., Sepers M., Henstridge C.M., Lassalle O., Neuhofer D., Martin H., et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun 2012, 3:1080.
14. Busquets-Garcia A., Gomis-González M., Guegan T., Agustín-Pavón C., Pastor A., Mato S., et al. Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nat Med 2013, 19:603-607.
15. Straiker A., Min K.T., Mackie K. Fmr1 deletion enhances and ultimately desensitizes CB(1) signaling in autaptic hippocampal neurons. Neurobiol Dis 2013, 56:1-5.
16. Detrait E., Hanon E., Dardenne B., Lamberty Y. The inhibitory avoidance test optimized for discovery of cognitive enhancers. Behavior Res Methods 2009, 41:805-811.
17. Liu Z.H., Smith C.B. Dissociation of social and nonsocial anxiety in a mouse model of fragile X syndrome. Neurosci Lett 2009, 454:62-66.
18. Mazzola C., Medalie J., Scherma M., Panlilio L.V., Solinas M., Tanda G., et al. Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors. Learn Mem 2009, 16:332-337.
19. Hill M.N., Kumar S.A., Filipski S.B., Iverson M., Stuhr K.L., Keith J.M., et al. Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry 2013, 18:1125-1135.
20. Gray J.M., Vecchiarelli H.A., Morena M., Lee T.T., Hermanson D.J., Kim A.B., et al. Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. J Neurosci 2015, 35:3879-3892.
21. Mines M.A., Yuskaitis C.J., King M.K., Beurel E., Jope R.S. GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS One 2010, 5:e9706.
22. Heitzer A.M., Roth A.K., Nawrocki L., Wrenn C.C., Valdovinos M.G. Brief report: altered social behavior in isolation-reared Fmr1 knockout mice. J Autism Dev Disord 2013, 43:1452-1458.
23. Kano M., Ohno-Shosaku T., Hashimotodani Y., Uchigashima M., Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009, 89:309-380.
24. Tang A.H., Alger B.E. Homer protein-metabotropic glutamate receptor binding regulates endocannabinoid signaling and affects hyperexcitability in a mouse model of fragile X syndrome. J Neurosci 2015, 35:3938-3945.
25. Ronesi J.A., Huber K.M. Homer interactions are necessary for metabotropic glutamate receptor-induced long-term depression and translational activation. J Neurosci 2008, 28:543-547.
26. Melis M., Greco B., Tonini R. Interplay between synaptic endocannabinoid signaling and metaplasticity in neuronal circuit function and dysfunction. Eur J Neurosci 2014, 39:1189-1201.